MBRX Quote, Financials, Valuation and Earnings

SeaStar Medical Holding has a net margin of -- compared to Moleculin Biotech's net margin of -1287.37%. Moleculin Biotech's return on equity of -- beat SeaStar Medical Holding's return on equity of --.

Moleculin Biotech has a consensus price target of $7.00, signalling upside risk potential of 2142.15%. On the other hand SeaStar Medical Holding has an analysts' consensus of $7.00 which suggests that it could grow by 1627.97%. Given that Moleculin Biotech has higher upside potential than SeaStar Medical Holding, analysts believe Moleculin Biotech is more attractive than SeaStar Medical Holding.

Moleculin Biotech has a beta of 1.562, which suggesting that the stock is 56.242% more volatile than S&P 500. In comparison SeaStar Medical Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Moleculin Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SeaStar Medical Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech pays -- of its earnings as a dividend. SeaStar Medical Holding pays out -- of its earnings as a dividend.

Moleculin Biotech quarterly revenues are --, which are smaller than SeaStar Medical Holding quarterly revenues of $293K. Moleculin Biotech's net income of -$6.4M is lower than SeaStar Medical Holding's net income of -$3.8M. Notably, Moleculin Biotech's price-to-earnings ratio is -- while SeaStar Medical Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech is -- versus -- for SeaStar Medical Holding. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -- compared to Moleculin Biotech's net margin of -311.07%. Moleculin Biotech's return on equity of -- beat Macrogenics's return on equity of -58.23%.

Moleculin Biotech has a consensus price target of $7.00, signalling upside risk potential of 2142.15%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 252.94%. Given that Moleculin Biotech has higher upside potential than Macrogenics, analysts believe Moleculin Biotech is more attractive than Macrogenics.

Moleculin Biotech has a beta of 1.562, which suggesting that the stock is 56.242% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.652, suggesting its more volatile than the S&P 500 by 65.244%.

Moleculin Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Moleculin Biotech quarterly revenues are --, which are smaller than Macrogenics quarterly revenues of $13.2M. Moleculin Biotech's net income of -$6.4M is higher than Macrogenics's net income of -$41M. Notably, Moleculin Biotech's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech is -- versus 0.49x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -- compared to Moleculin Biotech's net margin of -271.3%. Moleculin Biotech's return on equity of -- beat Spero Therapeutics's return on equity of -108.26%.

Moleculin Biotech has a consensus price target of $7.00, signalling upside risk potential of 2142.15%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 70.07%. Given that Moleculin Biotech has higher upside potential than Spero Therapeutics, analysts believe Moleculin Biotech is more attractive than Spero Therapeutics.

Moleculin Biotech has a beta of 1.562, which suggesting that the stock is 56.242% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.313, suggesting its more volatile than the S&P 500 by 31.286%.

Moleculin Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Moleculin Biotech quarterly revenues are --, which are smaller than Spero Therapeutics quarterly revenues of $5.1M. Moleculin Biotech's net income of -$6.4M is higher than Spero Therapeutics's net income of -$13.9M. Notably, Moleculin Biotech's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech is -- versus 5.66x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -- compared to Moleculin Biotech's net margin of -15.19%. Moleculin Biotech's return on equity of -- beat Zevra Therapeutics's return on equity of -198.46%.

Moleculin Biotech has a consensus price target of $7.00, signalling upside risk potential of 2142.15%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.71 which suggests that it could grow by 141.27%. Given that Moleculin Biotech has higher upside potential than Zevra Therapeutics, analysts believe Moleculin Biotech is more attractive than Zevra Therapeutics.

Moleculin Biotech has a beta of 1.562, which suggesting that the stock is 56.242% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 2.011, suggesting its more volatile than the S&P 500 by 101.078%.

Moleculin Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Moleculin Biotech quarterly revenues are --, which are smaller than Zevra Therapeutics quarterly revenues of $20.4M. Moleculin Biotech's net income of -$6.4M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Moleculin Biotech's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech is -- versus 10.94x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.